Kornimate/medical-research-clean huggingface dataset:
behavioral weight loss and exercise after treatment (beat)

Conditions: Breast Cancer

Summary: overweight and physically inactive breast cancer survivors are at increased risk of breast cancer recurrence and mortality. cancer treatment-related changes that likely mediate weight loss and exercise success include the long term effects such as fatigue, psychological distress and impaired executive (cognitive) function. this study will explore the variability in how breast cancer survivors respond to a behavioral weight loss intervention. the primary objectives include determining the degree to which success with a behavioral weight loss intervention in overweight breast cancer survivors is explained by measures of executive function as measured with task performance at 6 and 12 months and associated brain function imaging (fmri), collected at baseline only.additionally, the study is designed to determine the degree to which selected measures of cancer-related symptoms account for variance in the success of breast cancer survivors at 6 and 12 months following entry into a behavioral weight loss and exercise intervention.


Eligibility criteria:
inclusion criteria: * breast cancer diagnosis * received surgery +/- chemotherapy +/- radiation for treatment of a stage i, ii or iii breast cancer. ongoing treatment with monoclonal antibodies and/or anti-estrogen therapy is acceptable * completion of initial therapy 6 weeks prior to study initiation * bmi of 27-45 kg/m\^2 exclusion criteria: * prior diagnosis of malignancy other than non-melanoma skin cancer (i.e. prior non-melanoma skin cancer is not an exclusion criteria) * medical conditions that limit food choices such as celiac sprue or inflammatory bowel disease * inability to walk on flat ground (or a treadmill) at 2.5 mph for 5 minutes * age \ 70 * presence of body metal * psychotic or central nervous system impairment that would limit compliance with study requirements, including dementia * evidence of metastatic disease * symptomatic heart disease (chest pain or equivalent with activity) * exercise limiting pulmonary disease or need for oxygen to exercise * individuals taking mood stabilizing medications including: lithium, valproic acid, also called divalproex sodium (depakote), carbamazepine (tegretol), lamotrigine (lamictal), oxcarbazepine (trileptal), olanzapine (zyprexa), aripiprazole (abilify), risperidone (risperdal), ziprasidone (geodon), clozapine (clorazil) * participants with an active neurologic disorder that affects the central nervous system, including seizures, and parkinson's disease * weight loss of \>10 lbs in the previous 6 months * participation in \> 150 minutes of moderate intensity activity by self report, unless activity level by accelerometer is less than 150 minutes of moderate intensity activity

Keywords: breast cancer exercise weight loss executive function breast cancer survivor
virtual reality exposure versus in vivo exposure for fear of heights

Conditions: Fear of Heights; Acrophobia; Specific Phobia; Anxiety Disorder

Summary: this study randomly assigned 114 participants with significant fear of heights to one of three conditions: a) a single session of virtual reality exposure; b) a single session of in vivo exposure; or c) a control condition. the aim of this study was to compare the efficacy of virtual reality exposure to the efficacy of in vivo exposure or no exposure for participants with significant fear of heights.


Eligibility criteria:
inclusion criteria: * score \>= 45 on the acrophobia questionnaire (aq) exclusion criteria: * already receiving therapy specifically for fear of heights. * has any contraindications to using a virtual reality headset.
metformin for prevention gestational diabetes in pregnant women with polycystic ovarian syndrome

Conditions: Polycystic Ovary Syndrome; Diabetes, Gestational

Summary: randomized, placebo controlled clinical trial that evaluate the role of taking metformin therapy during pregnancy in women with polycystic ovarian syndrome(pcos) in reducing the development of gestational diabetes(gdm) and improving pregnancy outcomes.

the study will include a total of 80 pregnant women who fulfill the inclusion and exclusion criteria. participants will be distributed into two groups : group a: active one (40 women) will receive metformin in a dose of 1500mg per day (500mg every 8hrs in the middle of meal), starting from 12th week of gestation till delivery. group b: control group (40 women) will receive placebo which will be folic acid 500 micro gram which looks like metformin tablet. 80 opaque envelope will be numbered serially from 1-80, in each envelope paper containing the group to which the participants will be allocated according to randomization table .the envelopes will be put in one box and when the first patient arrives the first envelope will be open and the patient will be allocated according to the paper inside. detection of glucose intolerance will be done using oral glucose tolerance test (ogtt), which based on 75 gm to exclude any case of pre-gestational dm. bmi and blood pressure will be also assessed for all cases at entry of the study. follow up of all cases in antenatal care clinic, with clinical assessment including weight gain, blood pressure, urine examination for proteinuria and fetal well being tests. detection of development of gdm or even glucose intolerance will be by using (ogtt), which based on 75 gm glucose between 24th-28th wk and also can be repeated between 32th- 34th wk of pregnancy.

Eligibility criteria:
inclusion criteria: * all women had confirmed diagnosis of pcos before pregnancy according to revised 2003 rotterdam criteria. * age more than 20 and more than 40 years. * bmi ranging from (25_35 ) * written and signed informed consent is given from the patient to participate in the study. exclusion criteria: * women with pre-gestational diabetes mellitus confirmed by 2hrs ogtt. * patients who take metformin in the first 12 wk of pregnancy. * patients who are unwilling to participate in the study.

Keywords: diabetes mellitus pregnancy
omics signature in the diagnosis of hypertension

Conditions: Hypertension

Summary: the purpose of this study is to assess the validity and usefulness of omics signatures for improved identification and risk stratification of patients with endocrine hypertension and stratification of patients with primary hypertension.

arterial hypertension is the most important cause of death in the world. at referral hypertension centers about 25% of patients have a single cause for hypertension, so-called secondary hypertension, mostly of endocrine, adrenal origin (primary aldosteronism, pheochromocytoma/ paraganglioma, cushing's syndrome). this rate steps up to 50% in patients with drug resistant hypertension. proper treatment of secondary hypertension improves prognosis considerably but depends on adequate diagnosis. classically the diagnosis of such forms of hypertension rests on cumbersome biochemical and imaging procedures that may not completely take away uncertainty. modern '-omics' techniques (genomics, metabolomics, proteomics of plasma and urine) may allow faster and better diagnosis. in addition, they may provide a basis for stratification of hypertensive patients that do not have a identifiable cause of hypertension, so-called primary hypertension. this stratification may help predicting response to antihypertensive drugs and determining prognosis and thus, help to establish personalized medicine in hypertension care.

Eligibility criteria:
inclusion criteria: * aged from 18 to 75 years old * a signed and dated informed consent form * a diagnosis of hypertension defined either as: * use of antihypertensive drug (s) * arterial hypertension: in untreated patients this must be confirmed by daytime ambulatory blood pressure monitoring (abpm), or home blood pressure monitoring, with blood pressure higher or equal to 135 mmhg for systolic blood pressure and/or higher or equal to 85 mmhg for diastolic blood pressure. in order to be eligible to participate in the nested case control study, a subject must also meet the following criteria: - a conformed diagnosis of pa, ppgl or cs for case patients and pht (exclusion of secondary forms) for their matched counterparts exclusion criteria: * any severe comorbid conditions that, according to the attending physician, could decrease the life expectancy to less than 3 years * any active malignancy unrelated to adrenal disease or ppgl * guardianship for incapacity a potential control subject who meets any of the following criteria will be excluded from participation in the nested case controlled study in case of: * existence of any other forms of secondary hypertension such as renal artery stenosis, renal disease, munchausen's syndrome in which the patient induces hypertension regardless of method. * drug-induced (included factitious use of illicit substances) hypertension

Keywords: genomics proteomics metabolomics endocrine hypertension primary aldosteronism cushing syndrom pheochromocytoma
myorelaxation practice in paediatric anesthesia

Conditions: Neuromuscular Blockade

Summary: in retrospective data search the investigators will identified the percentage of patients with muscle relaxants administered during perioperative period. the block reversal, typ of drug, percentage of cases with and without reversal will be identified.

the actual percentage of surgeries with the muscle relaxants administered during perioperative period in paediatric patients remain unclear because many surgeries are being performed without muscle relaxation. in this retrospective study, the anesthesiology perioperative data from january 2016 till december 2016 in the tertiary center od pediatric anesthesia will be searched for the percentage of surgeries with muscle relaxants administered. type of surgery, age, weight, duration u surgery, muscle relaxants drug and percentage of block reversal will be identified.

Eligibility criteria:
inclusion criteria: * paediatric patients * the study period (1/2016-12/2016) * neuromuscular blocking agent administration during surgery exclusion criteria: * surgery without neuromuscular blockade

Keywords: neuromuscular blockade muscle relaxation muscle relaxant
bismuth quadruple therapy for helicobacter pylori rescue therapy of different tetracycline doses and frequencies.

Conditions: Helicobacter Pylori Infection

Summary: the researchers collect h.pylori-positive patients who need rescue therapy from the outpatient clinic. the subjects were randomized to receive a dose and frequency of tetracycline 500mg tid or qid of bismuth quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13c-urea breath test. calculate the eradication rates, adverse reaction rates and patient compliance of each group.

the researchers collect h.pylori-positive patients who need rescue therapy from the outpatient clinic. if the subject meets the selection criteria but not the exclusion criteria, and signs an informed consent form, the researchers randomized the subjects in groups: subjects received a dose and frequency of tetracycline 500mg tid or qid of bismuth quadruple eradication therapy. the medication of groups are as follows. 6-8 weeks after the eradication treatment, the subjects will review the 13c-urea breath test, and the researcher records the results. after all subjects were tested, the eradication rates, adverse reaction rates and patient compliance of each group were calculated. according to the dose and frequency of tetracycline, it is randomized into a tid treatment group and a qid treatment group. the two groups of bismuth quadruple regimens are the same, as follows: tid group: amoxicillin 1000mg bid+ tetracycline 500mg tid+ bismuth + esomeprazole 40mg bid qid group: amoxicillin 1000mg bid+ tetracycline 500mg qid+ bismuth + esomeprazole 40mg bid

Eligibility criteria:
inclusion criteria: 1. patients aged 18-70. 2. patients with h.pylori infection (positive for rapid urease test or 13c/14c-urea breath test). 3. patients who have previous failed h. pylori eradication treatment, and ≤ 2 times. exclusion criteria: 1. patients with serious underlying diseases, such as liver insufficiency (aspartate aminotransferase or alanine aminotransferase greater than 1.5 times the normal value), renal insufficiency (cr≥2.0mg/dl or glomerular filtration rate \<50 ml/min), immunosuppression, malignant tumors, coronary heart disease or coronary artery stenosis ≥75%. 2. patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial. 3. patients with active gastrointestinal bleeding. 4. patients with a history of upper gastrointestinal surgery. 5. patients allergic to treatment drugs. 6. patients with medication history of bismuth agents, antibiotics, proton pump inhibitor and other drugs within 4 weeks 7. patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse 8. patients who are unwilling or incapable to provide informed consents

Keywords: helicobacter pylori tetracycline bismuth quadruple therapy
rotem® obstetric hemorrhage pilot study

Conditions: High Risk Postpartum Hemorrhage (PPH)

Summary: this is a prospective observational study among women at high-risk of postpartum hemorrhage, in their third trimester who are admitted to labor \&delivery in spontaneous labor, for induction of labor, or for scheduled cesarean section.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years and able to provide consent 2. gestational age ≥ 34 weeks 3. ≥ 1 high-risk of postpartum hemorrhage criteria defined as either of: 1. nulliparous women admitted for induction of labor with unfavorable cervix (bishop's score \<5) 2. prior uterine surgery (\> 1 prior cesarean or myomectomy) 3. patients undergoing trial of labor after cesarean delivery 4. history of postpartum hemorrhage 5. ≥4 previous vaginal deliveries 6. multiple gestation 7. the presence of \> 2 uterine fibroids or fibroid \> 5 cm on any ultrasound during the pregnancy 8. planned magnesium sulfate use 9. placenta previa/accreta/increta/percreta exclusion criteria: 1. receipt of anticoagulation (prophylactic anticoagulation stopped 24 hours prior to sample collection is not an exclusion) 2. antepartum hemorrhage present on admission (\>500cc estimated blood loss (ebl)) 3. coagulation defects 4. thrombocytopenia with platelets count \<100,000 5. enrolled in the "tranexamic acid for the prevention of obstetrical hemorrhage after cesarean (txa)" (nct03364491) study or planned receipt of tranexamic acid (txa) prior to enrollment.

Keywords: high risk postpartum hemorrhage (pph) rotem pregnant women
feasibility of a consumer based accelerometer in monitoring outpatient physical activity: a study in patients with cancer and amyotrophic lateral sclerosis

Conditions: Prostate Cancer; Renal Cancer; Brain Cancer; ALS

Summary: this is a parallel group, single institution, prospective clinical study. the purpose of this study is to assess whether the jawbone up 24, a consumer based accelerometer, can be a feasible tool to study physical activity in cancer patients and patients with amyotrophic lateral sclerosis (als).


Eligibility criteria:
inclusion criteria: * patients \> = 18 years of age. * patient must be able to ambulate and complete the 6 minute walk test without use of a walker, cane, or any assist devices. * cancer patients or als patients who meet the following criteria: prostate cancer: * histologically confirmed prostate cancer. * patients who are initiating any chemotherarpy (examples are docetaxel, cabazitaxel, etc.) and/or hormone directed treatment for prostate cancer. examples of hormone directed therapy include gnrh agonist or antagonists (such as leuprolide, goserelin, triptorelin, histrelin and degarelix), androgen receptor blockers (such as bicalutamide or enzalutamide), or androgen biosynthesis inhibitors (such as abiraterone). renal cancer: * histologically confirmed renal cell carcinoma (rcc). * metastatic disease, in the opinion of the treating provider. * starting any systemic therapy for metastatic disease brain cancer: * histologically confirmed high grade glioma. * status post concurrent radiation therapy and daily temozolomide. * starting adjuvant temozolomide therapy. als patients who are: * already on a stable dose of riluzole for at least one month. * alsfrs-r with \<or equal to 2 point decline in last month. * must have alsfrs-r walking score of at least 3 or 4 and fvc at least 50% (to ensure patients are fit enough for ambulation and physical activity). - technology requirement: * patients will need to own a smart phone that can interface with the jawbone up 24. * patients willing to provide their own internet access for this study. this will include either a data plan or wi-fi access on the patient's smart phone for use of the jawbone app. they will also need internet access (through their smart phone or home computer) for setting up a sghix account. patients are welcome to use the free guest wi-fi access within the duke outpatient clinic area for the purpose of this study. * patients will need a home computer or adaptor with usb port to charge the jawbone up 24. exclusion criteria: * non-english speaking or inability to read and understand english * presence of cardiovascular disease that would make physical activity risky at the discretion of the provider. * any patient who is unable to comprehend and operate the activity tracker at the discretion of the enrolling provider.
efficiency of gonadotropin-releasing hormone (gnrh) agonist in preventing chemotherapy induced ovarian failure

Conditions: Fertility Preservation; Alkylating Agents; Lymphoma

Summary: chemotherapy drugs like alkylating agents are frequently used in various combined regimens to treat neoplastic and benign diseases. these drugs are definitely associated with premature ovarian failure (pof), resulting in an important decrease of the long-term quality of life and an increase of morbidity. a recent study showed that the patients treated by alkylating agents had a 4.52 fold higher risk to lose their ovarian function compared with those who were treated by other agents. the rate of pof after treatment ranged from 40 to 80%, according to the age of the patients and the total doses administered. young women who experience pof have to face with the prospects of infertility and to consider years of hormonal replacement therapy. the possibility of minimizing gonadal damage by administering of protective therapy during chemotherapy represents an attractive option for these patients. the aim of this study is to evaluate the protective effect on the ovarian function of the gonadotropin-releasing hormone agonist (gnrha) administered concomitantly to alkylating agents. preliminary data in the literature on animals (rat and monkeys) are promising. data in human are, however, highly controversial.


Eligibility criteria:
inclusion criteria: * women between 18 and 45 years old with lymphoma. * menarche \>2year * subject treated by chemotherapy-induced ovarian failure including alkylant agents (except less than 8 abvd) * presence of both ovaries (ovarian biopsy or hemiovariectomy for cryopreservation before treatment is accepted). * ability to give written informed consent exclusion criteria: * hormonal-sensible malignancy * chemotherapy or radiotherapy before the inclusion in the study * pelvic irradiation including the ovaries or tbi * pregnancy * patient weight above 110 kg * anamnesis of thrombo-embolic processes * severe hepatic or renal insufficiency * systolic blood pressure \>15mmhg or diastolic blood pressure \> 90mmhg * contraindication of im injection * relevant ovarian abnormalities (functional follicular cyst are tolerated) * anamnesis of premature ovarian failure or irregular cycle (repeated amenorrhoea \>2 months) * dubin-johnson and rotor syndrome

Keywords: ovarian failure, chemotherapy, lymphoma, gnrh agonist
assessment of plant-based program using shared medical appointment

Conditions: Chronic Disease; Nutrition, Healthy

Summary: evaluation of the impact of a whole food, plant-based (wfpb) program using shared medical appointments (smas) on reducing cardiovascular risk factors and weight loss in overweight/obese adults with at least one chronic disease

the study will use a single-arm with participants enrolled in three groups of 15 each (n=45) into the green wellness program: plants-2-plate, an established program focusing on wfpb predominant eating pattern in an academic primary care setting. the program will offer 14 smas in a period of 6 months. participants will attend the sma weekly for 3 months, followed by a monthly sma for the last 3 months of the intervention period. in the first session, participants will receive information about the program, and establish a health goal to be met at the end of the program. each weekly sma will have a nutrition education lesson, and feedback from the fnp, rn and rd after a brief assessment on health, medication adjustment, food choices, and shared ideas and experiences among the participants. at the end of the session, participants will set a small health goal to be followed during the week with assistance from the inter-professional team. the wfpb dietary approach includes vegetables, fruits, legumes, whole grains, seeds, nuts in small portion, elimination of all or most of animal foods, and reduction of processed food. participants will eat ad libitum. in addition, they will receive support to manage stress, improve quality of sleep, and increase physical activity during the sma.

Eligibility criteria:
inclusion criteria: * men and women \>18 years * either overweight (bmi \> 25kgm-2) or obese (bmi \>30 kgm-2) * diagnosis of one or more chronic diseases * own a smartphone or tablet that has reliable interned/data access * agrees to comply with all study requirements * can speak and understand english exclusion criteria: * diagnosis of cancer * previous participant in green wellness program: plants-2-plate * pregnant or planning to become pregnant * breastfeeding * concurrent weight loss program * plans to leave the city or usa for over 2 weeks within 6 months of enrollment

Keywords: whole food plant-based nutrition primary care setting
breathing exercise in pregnancy-induced hypertension

Conditions: Pregnancy Induced Hypertension

Summary: to determine the effects of breathing control vs alternate nostril breathing on maternal cardiovascular parameters in pregnancy and to determine the effect of breathing control vs alternate nostril breathing on fetal heart rate. many evidence-based studies show breathing exercises have beneficial and useful effects on the hypertensive population and also have positive effects on pregnancy-induced hypertension.

many breathing interventions are used for pregnancy-induced hypertension but the comparison is limited between two breathing techniques. in this study, a comparison will be carried out between evidence-based breathing techniques including breathing control and alternate nostril breathing to see which of these two exercises gives the best effects on females with pregnancy-induced hypertension.

Eligibility criteria:
inclusion criteria: * females with 3rd-trimester pregnancies included * bmi\<3 * diagnosed pregnancy-induced htn exclusion criteria: * an exaggerated response to exercise on bp ( 160/110 mmhg ) * uncontrolled diabetics or asthma * cardiac diseases * orthopedic complications * using anti-epileptic drugs and * hyperthyroidism or hypothyroidism

Keywords: breathing control alternate nostril breathing maternal cardiovascular parameters fetal heart rate